Alirocumab (anti-PCSK9)
CAS No. : 1245916-14-6
(Synonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9))
| Size | Price | Stock |
|---|---|---|
| 1mg | $425 | In-stock |
| 2mg | $680 | In-stock |
| 5mg | $1100 | In-stock |
| 10 mg | Get quote | |
| 50 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P9928A |
| M.Wt: | 1000.00 |
| Formula: | N/A |
| Purity: | >98 % |
| Solubility: | H2O |
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation[1][2][3][4][5][6][7][8][9][10][11].
IC50 & Target:PCSK9
In Vitro: Alirocumab (anti-PCSK9) (40 μg/mL, 24 h) alleviates basal PCSK9 overexpression in vascular smooth muscle cells (VSMCs) of obese insulin-resistant Zucker rats (OZR)[3].
Alirocumab (anti-PCSK9) (8 μg/mL, 72 h) attenuates Lp(a) secretion in primary human hepatocytes via inhibition of PCSK9[4].
Alirocumab (anti-PCSK9) (10 μg/mL, 24 h) inhibits lipid-induced inflammation in HepG2 cells[5].
In Vivo: Alirocumab (anti-PCSK9) (3-10 mg/kg, s.c., 18 weeks) inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin in APOE*3Leiden.CETP mice[6].
Alirocumab (anti-PCSK9) (16 mg/kg/week, s.c., on day 0, day 7, and day 14) boosts antioxidant status and halts inflammation in rat model of sepsis-induced nephrotoxicity via modulation of Nrf2/HO-1, PCSK9/HMGB1/NF-ᴋB/NLRP3 and Fractalkine/CX3CR1 hubs[7].
Alirocumab (anti-PCSK9) (50 mg/kg, s.c., weekly prior to exposure to the liquid diets) attenuates ethanol-induced neuronal injury in the brain and oxidative stress in rats s[8].
Alirocumab (anti-PCSK9) (1 mg/kg/week, s.c.) activates brown fat, increases hepatic uptake of cholesterol-rich TRL remnants, thereby lowering non-HDL-C, and increases HDL-C levels and cholesterol efflux capacity of HDL, further improving dyslipidemia in APOE*3-Leiden.CETP mice[9].
Alirocumab (anti-PCSK9) (10 mg/kg, s.c., 2 weeks) reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate[10].
Alirocumab (anti-PCSK9) (3-10 mg/kg, i.p., weekly for 16 weeks) reduces RAS, NLRP3 inflammasome, and cholecystokinin in lung tissue of obese mice[11].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Alirocumab (anti-PCSK9)
- Cat. No.:
- HY-P9928A
- Quantity:
Your information is safe with us.